Latest Insider Transactions at Artivion, Inc. (AORT)
This section provides a real-time view of insider transactions for Artivion, Inc. (AORT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARTIVION, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARTIVION, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 26
2024
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
31,312
-2.29%
|
$626,240
$20.27 P/Share
|
|
Feb 26
2024
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,514
-1.1%
|
$70,280
$20.27 P/Share
|
|
Feb 26
2024
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
3,048
-1.95%
|
$60,960
$20.27 P/Share
|
|
Feb 26
2024
|
Rochelle L. Maney VP, Quality |
SELL
Open market or private sale
|
Direct |
2,315
-2.71%
|
$46,300
$20.27 P/Share
|
|
Feb 26
2024
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,880
-0.88%
|
$57,600
$20.27 P/Share
|
|
Feb 26
2024
|
Andrew M Green VP Regulatory |
SELL
Open market or private sale
|
Direct |
2,403
-2.81%
|
$48,060
$20.27 P/Share
|
|
Feb 26
2024
|
Matthew A Getz VP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,313
-2.62%
|
$46,260
$20.27 P/Share
|
|
Feb 26
2024
|
Florian Tyrs VP, Global Operations |
SELL
Open market or private sale
|
Direct |
893
-3.92%
|
$17,860
$20.27 P/Share
|
|
Feb 23
2024
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,677
+4.2%
|
-
|
|
Feb 23
2024
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
188,053
+8.58%
|
-
|
|
Feb 23
2024
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,856
+7.45%
|
-
|
|
Feb 23
2024
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Grant, award, or other acquisition
|
Direct |
30,830
+11.95%
|
-
|
|
Feb 23
2024
|
Rochelle L. Maney VP, Quality |
BUY
Grant, award, or other acquisition
|
Direct |
17,677
+12.53%
|
-
|
|
Feb 23
2024
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
37,832
+7.29%
|
-
|
|
Feb 23
2024
|
Andrew M Green VP Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
21,380
+14.71%
|
-
|
|
Feb 23
2024
|
Matthew A Getz VP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
20,028
+13.54%
|
-
|
|
Feb 23
2024
|
Lance A Berry Executive VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
37,000
+31.88%
|
-
|
|
Feb 23
2024
|
Florian Tyrs VP, Global Operations |
BUY
Grant, award, or other acquisition
|
Direct |
6,537
+22.29%
|
-
|
|
Feb 23
2024
|
Robert C Thomson VP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
8,165
+38.05%
|
-
|
|
Feb 20
2024
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,695
-0.68%
|
$30,510
$18.86 P/Share
|
|
Feb 20
2024
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
3,527
-0.88%
|
$63,486
$18.86 P/Share
|
|
Feb 20
2024
|
Rochelle L. Maney VP, Quality |
SELL
Open market or private sale
|
Direct |
407
-1.38%
|
$7,326
$18.86 P/Share
|
|
Feb 20
2024
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,556
-0.98%
|
$46,008
$18.86 P/Share
|
|
Feb 20
2024
|
Matthew A Getz VP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,695
-2.82%
|
$30,510
$18.86 P/Share
|
|
Feb 20
2024
|
Florian Tyrs VP, Global Operations |
SELL
Open market or private sale
|
Direct |
249
-1.51%
|
$4,482
$18.86 P/Share
|
|
Feb 20
2024
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
72,069
-4.01%
|
$1,297,242
$18.86 P/Share
|
|
Feb 20
2024
|
James P Mackin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
59,225
+8.84%
|
$947,600
$16.3 P/Share
|
|
Jan 02
2024
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
21,229
-13.72%
|
$382,122
$18.0 P/Share
|
|
Jan 02
2024
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
21,229
+12.06%
|
$339,664
$16.3 P/Share
|
|
Jan 02
2024
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,562
-9.53%
|
$244,116
$18.0 P/Share
|
|
Jan 02
2024
|
John E Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,562
+8.7%
|
$216,992
$16.3 P/Share
|
|
Dec 15
2023
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
14,397
-10.4%
|
$273,543
$19.0 P/Share
|
|
Dec 15
2023
|
Amy Horton VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,397
+9.42%
|
$230,352
$16.3 P/Share
|
|
Dec 06
2023
|
Lance A Berry Executive VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
42,064
+50.0%
|
$715,088
$17.83 P/Share
|
|
Dec 06
2023
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,191
+14.0%
|
$343,247
$17.83 P/Share
|
|
Nov 27
2023
|
Amy Horton VP, Chief Accounting Officer |
SELL
Bona fide gift
|
Direct |
1,750
-1.66%
|
$29,750
$17.51 P/Share
|
|
Nov 27
2023
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,101
-1.95%
|
$35,717
$17.34 P/Share
|
|
Aug 08
2023
|
Florian Tyrs VP, Global Operations |
BUY
Grant, award, or other acquisition
|
Direct |
2,107
+11.32%
|
$33,712
$16.79 P/Share
|
|
Jun 09
2023
|
Robert C Thomson VP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
5,126
+50.0%
|
$76,890
$15.49 P/Share
|
|
Jun 07
2023
|
Matthew A Getz VP, Human Resources |
SELL
Open market or private sale
|
Direct |
6,329
-17.24%
|
$94,935
$15.88 P/Share
|
|
Jun 06
2023
|
Marna P Borgstrom Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,709
+21.02%
|
-
|
|
Jun 06
2023
|
Daniel J Bevevino Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,709
+6.6%
|
-
|
|
Jun 06
2023
|
Thomas F Ackerman Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,709
+6.61%
|
-
|
|
Jun 06
2023
|
James Bullock Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,709
+14.77%
|
-
|
|
Jun 06
2023
|
Jeffrey H Burbank Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,709
+19.08%
|
-
|
|
Jun 06
2023
|
Jon W Salveson Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,709
+7.65%
|
-
|
|
Jun 06
2023
|
Elizabeth A Hoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,709
+34.09%
|
-
|
|
Jun 06
2023
|
Anthony B. Semedo Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,709
+20.53%
|
-
|
|
Jun 06
2023
|
Dennis B Maier SVP, Operations |
SELL
Open market or private sale
|
Direct |
16,254
-16.11%
|
$243,810
$15.31 P/Share
|
|
Mar 02
2023
|
Dennis B Maier SVP, Operations |
SELL
Open market or private sale
|
Direct |
1,121
-2.15%
|
$14,573
$13.41 P/Share
|